Therapeutic drug monitoring-Does it really matter?
- PMID: 39739997
- DOI: 10.1111/bcp.16387
Therapeutic drug monitoring-Does it really matter?
References
REFERENCES
-
- Eichelbaum M, Ingelman‐Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med. 2006;57(1):119‐137. doi:10.1146/annurev.med.56.082103.104724
-
- Jukic M, Milosavljević F, Molden E, Ingelman‐Sundberg M. Pharmacogenomics in treatment of depression and psychosis: an update. Trends Pharmacol Sci. 2022;43(12):1055‐1069. doi:10.1016/j.tips.2022.09.011
-
- Holford N, Ma G, Metz D. TDM is dead. Long live TCI! Br J Clin Pharmacol. 2022;88(4):1406‐1413. doi:10.1111/bcp.14434
-
- Lemaitre F, Hesselink DA. TDM is alive and kicking! Ther Drug Monit. 2023;45(1):3‐5. doi:10.1097/FTD.0000000000001034
-
- Minichmayr IK, Dreesen E, Centanni M, et al. Model‐informed precision dosing: state of the art and future perspectives. Adv Drug Deliv Rev. 2024;17:115421. doi:10.1016/j.addr.2024.115421
Publication types
Grants and funding
- 211634Pj01H/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
- 243519Pj01H/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
- HL is funded through grants obtained from the Swed/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
- 2020-02367/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
- 2024-03166/HL is funded through grants obtained from the Swedish Cancer Foundation (Cancerfonden)
LinkOut - more resources
Full Text Sources